Aktiia Raises CHF 27 Million to Accelerate Innovation in Hypertension Management

Switzerland-based Aktiia has closed a CHF 27 million (US$ 30 million) financing round led by Redalpine, with participation from an international syndicate of investors including Khosla Ventures, Molten, Translink Capital, Verve and 415 Capital, to accelerate its mission to reduce the global burden of hypertension by providing breakthrough insights into blood pressure management through AI-driven technology currently used by over 60,000 customers and dozens of healthcare organisations.

Aktiia’s CE-marked device is currently available in seven European markets and is approved as a medical device in 44 countries worldwide. Based on more than 20 years of research, Aktiia’s technology offers unparalleled innovation and simplicity in blood pressure data collection and machine learning modelling, providing personalised, continuous and medical-grade blood pressure and heart rate data. Aktiia empowers people, researchers and clinicians with unique blood pressure data, paving the way for a new understanding of hypertension and personalized patient care.

With over 300 million data points from around the world, Aktiia’s continuous blood pressure dataset is growing exponentially, creating countless opportunities for deep learning about public health trends and patterns to advance our understanding of blood pressure and provide predictive insights on a global scale.